标题
SGLT2 inhibition to address the unmet needs in diabetic nephropathy
作者
关键词
-
出版物
DIABETES-METABOLISM RESEARCH AND REVIEWS
Volume -, Issue -, Pages e3171
出版商
Wiley
发表日期
2019-04-18
DOI
10.1002/dmrr.3171
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- US Renal Data System 2017 Annual Data Report: Epidemiology of Kidney Disease in the United States
- (2018) Rajiv Saran et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data from the CANVAS Program
- (2018) Brendon L. Neuen et al. CIRCULATION
- The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
- (2018) Merlin C. Thomas et al. DIABETOLOGIA
- Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
- (2018) Chiara Ghezzi et al. DIABETOLOGIA
- Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study
- (2018) Giuseppe Penno et al. DIABETOLOGIA
- Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
- (2018) Hiddo J.L. Heerspink et al. KIDNEY INTERNATIONAL
- Sodium–glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice
- (2018) Shinji Tanaka et al. KIDNEY INTERNATIONAL
- Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin
- (2018) David Z.I. Cherney et al. KIDNEY INTERNATIONAL
- Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease
- (2018) Claire C J Dekkers et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection
- (2018) Hiroyuki Umino et al. Scientific Reports
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
- (2018) Vlado Perkovic et al. Lancet Diabetes & Endocrinology
- Combining SGLT2 Inhibition With a Thiazolidinedione Additively Attenuate the Very Early Phase of Diabetic Nephropathy Progression in Type 2 Diabetes Mellitus
- (2018) Eugene Han et al. Frontiers in Endocrinology
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy
- (2017) Xiaoxin X. Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits
- (2017) Jens Oellgaard et al. KIDNEY INTERNATIONAL
- Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
- (2017) Adeera Levin et al. LANCET
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis
- (2017) Xiaoling Cai et al. Obesity
- Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients
- (2017) Mohsen Mazidi et al. Journal of the American Heart Association
- Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
- (2017) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
- (2017) Christoph Wanner et al. CIRCULATION
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment
- (2016) Paola Fioretto et al. DIABETOLOGIA
- Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
- (2016) Volker Vallon et al. DIABETOLOGIA
- Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial
- (2016) Peter Gæde et al. DIABETOLOGIA
- Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014
- (2016) Maryam Afkarian et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
- (2016) Hiddo J. L. Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease
- (2016) Yanling Zhang et al. PLoS One
- Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes
- (2016) Seok Joon Shin et al. PLoS One
- Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
- (2016) Linda A. Gallo et al. Scientific Reports
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Understanding EMPA-REG OUTCOME
- (2015) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
- (2014) Marko Škrtić et al. DIABETOLOGIA
- Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport
- (2014) M. A. Abdul-Ghani et al. JOURNAL OF INTERNAL MEDICINE
- Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis
- (2014) H. J. Lambers Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes
- (2014) David Z.I. Cherney et al. KIDNEY INTERNATIONAL
- Inhibition of Kidney Proximal Tubular Glucose Reabsorption Does Not Prevent against Diabetic Nephropathy in Type 1 Diabetic eNOS Knockout Mice
- (2014) Muralikrishna Gangadharan Komala et al. PLoS One
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes
- (2013) Kazuhiro Hasegawa et al. NATURE MEDICINE
- The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease
- (2012) Jan Skupien et al. KIDNEY INTERNATIONAL
- Suppression of Oxidative Stress by -Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor
- (2012) T. Shimazu et al. SCIENCE
- Early Renal Function Decline in Type 2 Diabetes
- (2011) M. E. Pavkov et al. Clinical Journal of the American Society of Nephrology
- An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
- (2011) Frank A. Holtkamp et al. KIDNEY INTERNATIONAL
- Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes
- (2011) Hermann Haller et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule
- (2010) V. Vallon et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Solute carrier family 2, member 9 and uric acid homeostasis
- (2009) Chris Cheeseman CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes
- (2009) Michael Mauer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes
- (2008) Peter Gæde et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search